#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs

#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs

292940

#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. A majority of the relapsing-remitting multiple sclerosis (RRMS) patients given Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did not need further disease-modifying therapy (DMT) for at least four years after their last trial dose, a recent analysis found. This held even with more than half of the patients…

You must be logged in to read/download the full post.